Iterum Therapeutics plc (ITRMF) Net Income (2017 - 2025)

Iterum Therapeutics' Net Income history runs 9 years deep, the most recent figure standing at -$9.0 million for Q3 2025.

• In Q3 2025, Net Income fell 47.34% year-over-year to -$9.0 million; the TTM figure through Sep 2025 stood at $1.2 million (down 86.03% YoY), while the FY2024 annual figure was $3.4 million, up 204.16% from the prior year.
• Net Income for Q3 2025 stood at -$9.0 million, down from -$6.5 million in the prior quarter.
• The five-year high for Net Income was $27.1 million in Q4 2023, with the low at -$98.9 million in Q1 2021.
• The 5-year median for Net Income is -$5.1 million (2022), against an average of -$8.0 million.
• The sharpest annual moves came in 2022 and 2023: Net Income tumbled 878.11% in 2022, then jumped 633.18% in 2023.
• Iterum Therapeutics' Net Income stood at -$4.1 million in 2021, then retreated by 22.71% to -$5.1 million in 2022, then surged by 633.18% to $27.1 million in 2023, then dropped by 20.3% to $21.6 million in 2024, then plunged by 141.51% to -$9.0 million in 2025.
• Business Quant data shows ITRMF's Net Income at -$9.0 million in Q3 2025, -$6.5 million in Q2 2025, and -$4.9 million in Q1 2025.